A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors
← catalyst calendarNCT06657144 · readout ≤ 530 d
Sponsored by Coherus Oncology, Inc. (industry) · CHRS — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
154estimated
Sites
30
Countries
Taiwan, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-04-01 | actual | When the study began enrolling |
| Primary completion | Jan 2028 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Jan 2028 | estimated | The whole study's end, after follow-up |
| First posted | 2024-10-24 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-15 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Metastatic Solid Tumor
- Advanced Solid Tumor
Interventions
- Drug: CHS-114
- Drug: Toripalimab
- Drug: 5 Fluorouracil
- Drug: Cisplatin
Primary outcome
what the primary-completion date above is the date OFNumber of Participants With Treatment-emergent Adverse Events (TEAEs)
measured From first dose of study drug until 90 days after the last dose of study drug (up to approximately 2.25 years)
Publications
- PMID 41423415 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · CHRS's whole pipeline · Catalyst calendar · Every registered study · What changed